Antibody Signals Higher MOGAD Recurrence Risk
A joint South Korea and UK study links the MOGα3 antibody to substantially higher recurrence rates in MOG antibody-associated disease.
Updated on Nov. 11, 2026 in Stroke
A joint research team from South Korea and the UK has identified the MOGα3 antibody as associated with a higher risk of recurrence in MOG antibody-associated disease. The findings were published in Neurology: Neuroimmunology & Neuroinflammation.
Why it matters
The study suggests that testing for this antibody could help identify patients at greater risk of relapse. Clinicians may be able to better anticipate recurrence in people with this condition, which can affect the brain, spinal cord and optic nerves.
The analysis covered 161 patients across South Korea and the UK, with one-year recurrence at 87.5% for antibody-positive patients versus 31.2% for antibody-negative patients. Whether these results will translate into established treatment protocols remains unconfirmed pending larger studies.
The players
Seoul National University Hospital
A leading South Korean teaching hospital that served as the lead institution for the joint research team studying MOG antibody-associated disease.
University of Oxford
A major British research university whose partner team contributed patient analysis to the joint study on MOG antibody-associated disease.
The details
The immune system produces antibodies that attack MOG, a protein that protects nerves, and researchers tested patient blood against seven structural forms of the protein rather than one. Analysis included 56 patients at Seoul National University Hospital, 49 patients across eight domestic hospitals, and a cohort from Oxford, UK.
Timeline
Within one year of onset: recurrence rates were measured for antibody-positive and antibody-negative patients.
- 2026-11-11
Seoul National University Hospital announced the research findings.
Health Landscape
Earlier MOG antibody tests examined reactions to only one of the protein's seven forms, which limited their ability to distinguish recurrence risk. This study's multi-form approach represents a refinement of how researchers characterize MOG antibody-associated disease.
Patients with MOG antibody-associated disease may one day have their recurrence risk assessed through antibody testing, which could inform monitoring decisions. Current findings do not yet change standard care, and anyone with symptoms should discuss them with a neurologist.
The takeaway
Testing for the MOGα3 antibody may eventually help clinicians identify people with MOG antibody-associated disease who face higher recurrence risk. Larger studies will determine whether this becomes part of routine practice.
Further reading
For broader context on related neurological conditions, explore our Stroke coverage.
More information
Read the full published study in Neurology: Neuroimmunology & Neuroinflammation.
Source note: This article includes information reported by 조선일보.
